Targeting elastase in bronchopulmonary dysplasia

American Journal of Respiratory and Critical Care Medicine

Volumn 184, Issue 5, 2011, Pages 496-497

  Morty, Rory E ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 PEPTIDASE INHIBITOR; ELAFIN; ELASTASE; ELASTIN; ENZYME INHIBITOR; GELATINASE B; STEROID; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ARTIFICIAL VENTILATION; EDITORIAL; ENZYME ACTIVITY; GENE TARGETING; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LUNG DYSPLASIA; MORBIDITY; MORTALITY; NEWBORN; OXYGEN THERAPY; PATHOGENESIS; PREMATURITY; PRIORITY JOURNAL; STEROID THERAPY; VERY LOW BIRTH WEIGHT;

ANIMALS; ELAFIN; LUNG; ORGANOGENESIS; PANCREATIC ELASTASE; PROTEASE INHIBITORS; RESPIRATION, ARTIFICIAL; RESPIRATORY INSUFFICIENCY;

EID: 80052474109     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201105-0930ED     Document Type: Editorial

References (13)

1. Northway WH, Rosan RC, Porter DY. Pulmonary disease following respiratory therapy of hyaline membrane disease: bronchopulmonary dysplasia. N Engl J Med 1967;276:357-368.
2. Jobe AH. The new bronchopulmonary dysplasia. Curr Opin Pediatr 2011;23:167-172.
3. Van Mater LJ. Epidemiology of bronchopulmonary dysplasia. Semin Fetal Neonatal Med 2009;14:358-366.
4. Thibeault DW, Mabry SM, Ekekezie II, Truog WE. Lung elastic tissue maturation and perturbations during the evolution of chronic lung disease. Pediatrics 2000;106:1452-1459.
5. Bruce MC, Schuyler M, Martin R, Starcher BC, Tomashefski JF, Wedig KE. Risk factors for the degradation of lung elastic fibers in the ventilated neonate. Am Rev Respir Dis 1992;146:204-212.
6. Pierce RA, Albertine KH, Starcher BC, Bohnsack JF, Carlton DP, Bland RD. Chronic lung injury in preterm lambs: disordered pulmonary elastin deposition. Am J Physiol 1997;272:L452-L460.
7. Kumarasamy A, Schmitt I, Nave AH, Reiss I, van der Horst I , Dony E, Roberts JD Jr, de Krijger RR, Tibboel D, SeegerW, et al. Lysyl oxidase activity is dysregulated during impaired alveolarization of mouse and human lungs. Am J Respir Crit Care Med 2009;180:1239-1252.
8. Hilgendorff A, Parai K, Ertsey R, Jain N, Navarro EF, Peterson JL, Tamosiuniene R, Nicolls MR, Starcher BC, Rabinovitch M, et al. Inhibiting lung elastase activity enables lung growth in mechanically ventilated newborn mice. Am J Respir Crit Care Med 2011; 184:537-546.
9. 1-proteinase inhibitor therapy for the prevention of chronic lung disease or prematurity: a randomized, controlled trial. Pediatrics 1998;101:89-94.
10. Alejandre-Alcázar MA, Kwapiszewska G, Reiss I, Amarie OV, Marsh LM, Sevilla-Pérez J, Wygrecka M, Eul B, Köbrich S, Hesse M, et al. Hyperoxia modulates TGF-β/BMP signaling in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2007;292:L537-L549.
11. Gauldie J, Galt T, Bonniaud P, Robbins C, Kelly M, Warburton D. Transfer of the active form of transforming growth factor-beta 1 gene to newborn rat lung induces changes consistent with bronchopulmonary dysplasia. Am J Pathol 2003;163:2575-2584. (Pubitemid 37466498)
12. Chen H, Sun J, Buckley S, Chen C, Warburton D, Wang XF, Shi W. Abnormal mouse lung alveolarization caused by Smad3 deficiency is a developmental antecedent of centrilobular emphysema. Am J Physiol Lung Cell Mol Physiol 2005;288:L683-L691. (Pubitemid 40404136)
13. Sallenave JM. Secretory leukocyte protease inhibitor and elafin/trappin- 2: versatile mucosal antimicrobials and regulators of immunity. Am J Respir Cell Mol Biol 2010;42:635-643.